Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell non-Hodg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• Revlimid (lenalidomide)
• Venclexa (venetoclax)

Snippet

Sponsor: Beth Christian | Conditions: B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING